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Migraine is a debilitating neurological disorder affecting around 1 in 7 people worldwide, 94 
but its molecular mechanisms remain poorly understood. Some debate exists over 95 
whether migraine is a disease of vascular dysfunction or a result of neuronal dysfunction 96 
with secondary vascular changes. Genome-wide association (GWA) studies have thus far 97 
identified 13 independent loci associated with migraine. To identify new susceptibility 98 
loci, we performed the largest genetic study of migraine to date, comprising 59,674 cases 99 
and 316,078 controls from 22 GWA studies. We identified 44 independent single 100 
nucleotide polymorphisms (SNPs) significantly associated with migraine risk (P < 5 × 10-101 
8) that map to 38 distinct genomic loci, including 28 loci not previously reported and the 102 
first locus identified on chromosome X. In subsequent computational analyses, the 103 
identified loci showed enrichment for genes expressed in vascular and smooth muscle 104 
tissues, consistent with a predominant theory of migraine that highlights vascular 105 
etiologies.  106 
 107 
Migraine is ranked as the third most common disease worldwide, with a lifetime prevalence of 108 
15-20%, affecting up to one billion people across the globe1,2. It ranks as the 7th most disabling 109 
of all diseases worldwide (or 1st most disabling neurological disease) in terms of years of life lost 110 
to disability1 and is the 3rd most costly neurological disorder after dementia and stroke3. There is 111 
debate about whether migraine is a disease of vascular dysfunction, or a result of neuronal 112 
dysfunction with vascular changes representing downstream effects not themselves causative 113 
of migraine4,5. However, genetic evidence favoring one theory versus the other is lacking. At the 114 
phenotypic level, migraine is defined by diagnostic criteria from the International Headache 115 
Society6. There are two prevalent sub-forms: migraine without aura is characterized by recurrent 116 
attacks of moderate or severe headache associated with nausea or hypersensitivity to light and 117 
sound. Migraine with aura is characterized by transient visual and/or sensory and/or speech 118 
symptoms usually followed by a headache phase similar to migraine without aura.  119 
 120 
Family and twin studies estimate a heritability of 42% (95% confidence interval [CI] = 36-47%) 121 
for migraine7, pointing to a genetic component of the disease. Despite this, genetic association 122 
studies have revealed relatively little about the molecular mechanisms that contribute to 123 
pathophysiology. Understanding has been limited partly because, to date, only 13 genome-wide 124 
significant risk loci have been identified for the prevalent forms of migraine8–11. In familial 125 
hemiplegic migraine (FHM), a rare Mendelian form of the disease, three ion transport-related 126 
genes (CACNA1A, ATP1A2 and SCN1A) have been implicated12–14. These findings suggest that 127 
 4 
mechanisms that regulate neuronal ion homeostasis might also be involved in migraine more 128 
generally, however, no genes related to ion transport have yet been identified for these more 129 
prevalent forms of migraine15. 130 
 131 
We performed a meta-analysis of 22 genome-wide association (GWA) studies, consisting of 132 
59,674 cases and 316,078 controls collected from six tertiary headache clinics and 27 133 
population-based cohorts through our worldwide collaboration in the International Headache 134 
Genetics Consortium (IHGC). This combined dataset contained over 35,000 new migraine 135 
cases not included in previously published GWA studies. Here we present the findings of this 136 
new meta-analysis, including 38 genomic loci, harboring 44 independent association signals 137 
identified at levels of genome-wide significance, which support current theories of migraine 138 
pathophysiology and also offer new insights into the disease. 139 
 140 
Results 141 
Significant associations at 38 independent genomic loci 142 
The primary meta-analysis was performed on all migraine samples available through the IHGC, 143 
regardless of ascertainment. These case samples included both individuals diagnosed with 144 
migraine by a doctor as well as individuals with self-reported migraine via questionnaires. Study 145 
design and sample ascertainment for each individual study is outlined in the Supplementary 146 
Note (and summarized in Supplementary Table 1). The final combined sample consisted of 147 
59,674 cases and 316,078 controls in 22 non-overlapping case-control samples (Table 1). All 148 
samples were of European ancestry. Before including the largest study from 23andMe, we 149 
confirmed that it did not contribute any additional heterogeneity compared to the other 150 
population and clinic-based studies (Supplementary Table 2). 151 
 152 
The 22 individual GWA studies completed standard quality control protocols (Online Methods) 153 
summarized in Supplementary Table 3. Missing genotypes were then imputed into each 154 
sample using a common 1000 Genomes Project reference panel16. Association analyses were 155 
performed within each study using logistic regression on the imputed marker dosages while 156 
adjusting for sex and other covariates where necessary (Online Methods and Supplementary 157 
Table 4). The association results were combined using an inverse-variance weighted fixed-158 
effects meta-analysis. Markers were filtered for imputation quality and other metrics (Online 159 
Methods) leaving 8,094,889 variants for consideration in our primary analysis. 160 
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 161 
Among these variants in the primary analysis, we identified 44 genome-wide significant SNP 162 
associations (P < 5 × 10-8) that are independent (r2 < 0.1) with regards to linkage disequilibrium 163 
(LD). We validated the 44 SNPs by comparing genotypes in a subset of the sample to those 164 
obtained from whole-genome sequencing (Supplementary Table 5). To help identify candidate 165 
risk genes from these, we defined an associated locus as the genomic region bounded by all 166 
markers in LD (r2 > 0.6 in 1000 Genomes, Phase I, EUR individuals) with each of the 44 index 167 
SNPs and in addition, all such regions in close proximity (< 250 kb) were merged. From these 168 
defined regions we implicate 38 distinct genomic loci in total for the prevalent forms of migraine, 169 
28 of which have not previously been reported (Figure 1).  170 
 171 
These 38 loci replicate 10 of the 13 previously reported genome-wide associations to migraine 172 
(Table 2). Six of the 38 loci contain a secondary genome-wide significant SNP (P < 5 × 10-8) not 173 
in LD (r2 < 0.1) with the top SNP in the locus (Table 2). Five of these secondary signals were 174 
found in known loci (at LRP1, PRDM16, FHL5, TRPM8, and TSPAN2), while the sixth was 175 
found within one of the 28 new loci (PLCE1). Therefore, out of the 44 LD-independent SNPs 176 
reported here, 34 are new associations to migraine. Three previously reported loci that were 177 
associated to subtypes of migraine (rs1835740 near MTDH to migraine with aura, rs10915437 178 
near AJAP1 to migraine clinical-samples, and rs10504861 near MMP16 to migraine without 179 
aura)8,11 show only nominal significance in the current meta-analysis (P = 5 × 10-3 for 180 
rs1835740, P = 4.4 × 10-5 for rs10915437, and P = 4.9 × 10-5 for rs10504861, Supplementary 181 
Table 6), however, these loci have since been shown to be associated to specific phenotypic 182 
features of migraine17 and therefore may require a more phenotypically homogeneous sample 183 
to be accurately assessed for association. Four out of 44 SNPs (at TRPM8, ZCCHC14, MRVI1, 184 
and CCM2L) exhibited moderate heterogeneity across the individual GWA studies (Cochran’s Q 185 
test p-value < 0.05, Supplementary Table 7) therefore at these markers we applied a random 186 
effects model18. 187 
 188 
Characterization of the associated loci 189 
In total, 32 of 38 (84%) loci overlap with transcripts from protein-coding genes, and 17 (45%) of 190 
these regions contain just a single gene (see Supplementary Figure 1 for regional plots of the 191 
38 genomic loci and Supplementary Table 8 for extended information on each locus). Among 192 
the 38 loci, only two contain ion channel genes (KCNK519 and TRPM820). Hence, despite 193 
previous hypotheses of migraine as a potential channelopathy5,21, the loci identified to date do 194 
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not support common variants in ion channel genes as strong susceptibility components in 195 
prevalent forms of migraine. However, three other loci do contain genes involved more generally 196 
in ion homeostasis (SLC24A322, ITPK123, and GJA124, Supplementary Table 9). 197 
 198 
Several of the genes have previous associations to vascular disease (PHACTR1,25,26 199 
TGFBR2,27  LRP1,28 PRDM16,29 RNF213,30 JAG1,31 HEY2,32 GJA133, ARMS234), or are 200 
involved in smooth muscle contractility and regulation of vascular tone (MRVI1,35 GJA1,36 201 
SLC24A3,37 NRP138). Three of the 44 migraine index SNPs have previously reported 202 
associations in the National Human Genome Research Institute (NHGRI) GWAS catalog at 203 
exactly the same SNP (rs9349379 at PHACTR1 with coronary heart disease39–41, coronary 204 
artery calcification42, and cervical artery dissection; rs11624776 at ITPK1 with thyroid hormone 205 
levels43; and rs11172113 at LRP1 with pulmonary function; Supplementary Table 10). Six of 206 
the loci harbor genes that are involved in nitric oxide signaling and oxidative stress (REST44, 207 
GJA145, YAP146, PRDM1647, LRP148, and MRVI149). 208 
 209 
From each locus we chose the nearest gene to the index SNP to assess gene expression 210 
activity in tissues from the GTEx consortium (Supplementary Figure 2). While we found that 211 
most of the putative migraine loci genes were expressed in many different tissue types, we 212 
could detect tissue specificity in certain instances whereby some genes showed significantly 213 
higher expression in a particular tissue group relative to the others. For instance four genes 214 
were more actively expressed in brain (GPR149, CFDP1, DOCK4, and MPPED2) compared to 215 
other tissues, whereas eight genes were specifically active in vascular tissues (PRDM16, 216 
MEF2D, FHL5, C7orf10, YAP1, LRP1, ZCCHC14, and JAG1). Many of the other putative 217 
migraine loci genes were actively expressed in more than one tissue group. 218 
 219 
Genomic inflation and LD-score regression analysis 220 
To assess whether the 38 loci harbor true associations with migraine rather than reflecting 221 
systematic differences between cases and controls (such as population stratification) we 222 
analyzed the genome-wide inflation of test statistics in our primary meta-analysis. As expected 223 
for a complex polygenic trait, the distribution of test statistics deviates from the null (genomic 224 
inflation factor λGC = 1.24, Supplementary Figure 3) which is in line with other large GWA study 225 
meta-analyses50–53. Since much of the inflation in a polygenic trait arises from LD between the 226 
causal SNPs and many other neighboring SNPs in the local region, we LD-pruned the meta-227 
analysis results to create a set of LD-independent markers (i.e. in PLINK54 with a 250-kb sliding 228 
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window and r2 > 0.2). The resulting genomic inflation was reduced (λGC = 1.15, Supplementary 229 
Figure 4) and likely reflects the inflation remaining due to the polygenic signal at many 230 
independent loci, including those not yet significantly associated. 231 
 232 
To confirm that the observed inflation is primarily coming from true polygenic signal, we 233 
analyzed the meta-analysis results from all imputed markers using LD-score regression55. This 234 
method tests for a linear relationship between marker test statistics and LD score, defined as 235 
the sum of r2 values between a marker and all other markers within a 1-Mb window. The primary 236 
analysis results show a linear relationship between association test statistics and LD-score 237 
(Supplementary Figure 5) and estimate that the majority (88.2%) of the inflation in test 238 
statistics can be ascribed to true polygenic signal rather than population stratification or other 239 
confounders. These results are consistent with the theory of polygenic disease architecture 240 
shown previously by both simulation and real data for GWAS samples of similar size56.  241 
 242 
Migraine subtype analyses 243 
To elucidate pathophysiological mechanisms underpinning the migraine aura, we performed a 244 
secondary analysis by creating two subsets that included only samples with the subtypes; 245 
migraine with aura and migraine without aura. These subsets only included those studies where 246 
sufficient information was available to assign a diagnosis of either subtype according to 247 
classification criteria standardized by the International Headache Society (IHS)6. For the 248 
population-based study samples this involved questionnaires, whereas for the clinic-based 249 
study samples the diagnosis was assigned on the basis of a structured interview by telephone 250 
or in person. A stricter diagnosis is required for these migraine subtypes as the migraine aura 251 
specifically is challenging to distinguish from other neurological features that can present as 252 
symptoms from unrelated conditions. 253 
 254 
As a result, the migraine subtype analyses consisted of considerably smaller sample sizes 255 
compared to the main analysis (6,332 cases vs. 144,883 controls for migraine with aura and 256 
8,348 cases vs. 139,622 controls for migraine without aura, see Table 1). As with the primary 257 
migraine analysis, the test statistics for migraine with aura or migraine without aura were 258 
consistent with underlying polygenic architecture rather than other potential sources of inflation 259 
(Supplementary Figure 6 and 7). For the migraine without aura subset analysis we found 260 
seven independent genomic loci (near TSPAN2, TRPM8, PHACTR1, FHL5, ASTN2, near 261 
FGF6, and LRP1) to be significantly associated (Supplementary Table 11 and Supplementary 262 
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Figure 8). All seven of these loci were already identified in the primary analysis of ‘all migraine’ 263 
types, possibly reflecting the fact that migraine without aura is the most common form of 264 
migraine (around 2 in 3 cases) and likely drives the association signals in the primary analysis. 265 
Notably, no loci were associated to migraine with aura in the other subset analysis 266 
(Supplementary Figure 9). 267 
 268 
To investigate whether excess heterogeneity could be contributing to the lack of associations in 269 
migraine with aura, we performed a heterogeneity analysis between the two subgroups. First we 270 
created two subsets of the migraine with aura and migraine without aura datasets from which 271 
none of the case or control individuals were overlapping (Supplementary Table 12). Then we 272 
selected the 44 LD-independent SNPs associated from the primary analysis and used a 273 
random-effects model to combine the migraine with aura and migraine without aura samples in 274 
a meta-analysis that allows for heterogeneity between the two migraine groups57. We found little 275 
heterogeneity with only seven of the 44 SNPs (at REST, MPPED2, PHACTR1, ASTN2, MEF2D, 276 
PLCE1, and MED14) exhibiting some signs of heterogeneity across subtype groups 277 
(Supplementary Table 13). 278 
 279 
Credible sets of markers within each locus 280 
For each of the 38 migraine-associated loci, we defined a credible set of markers that could 281 
plausibly be considered as causal using a Bayesian-likelihood based approach58. This method 282 
incorporates evidence from association test statistics and the LD structure between SNPs in a 283 
locus (Online Methods). A list of the credible set SNPs obtained for each locus is provided in 284 
Supplementary Table 14. We found three instances (in RNF213, PLCE1, and MRVI1) where 285 
the association signal could be credibly attributed to exonic missense polymorphisms 286 
(Supplementary Table 15). However, most of the credible markers at each locus were either 287 
intronic or intergenic, which is consistent with the theory that most variants detected by GWA 288 
studies involve regulatory effects on gene expression rather than disrupting protein 289 
structure59,60. 290 
 291 
Overlap with eQTLs in specific tissues 292 
To try to identify specific migraine loci that might influence gene expression, we used previously 293 
published datasets that catalog expression quantitative trait loci (eQTLs) in either of two 294 
microarray-based studies from peripheral venous blood (N1 = 3,754) or from human brain cortex 295 
tissue (N2 = 550). Additionally, we used a third study based on RNAseq data from a collection of 296 
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42 tissues and three cell lines (N3 = 1,641) from the Genotype-Tissue Expression (GTEx) 297 
consortium61. While this data has the advantage of a diverse tissue catalog, the number of 298 
samples per tissue is relatively small (Supplementary Table 16) compared to the two 299 
microarray datasets, possibly resulting in reduced power to detect significant eQTLs in some 300 
tissues. Using these datasets we applied a method based on the overlap of migraine and eQTL 301 
credible sets to identify eQTLs that could explain associations at the 38 migraine loci (Online 302 
Methods). This approach merged the migraine credible sets defined above with credible sets 303 
from cis-eQTL signals within a 1-Mb window and tested if the association signals between the 304 
migraine and eQTL credible sets were correlated. After adjusting for multiple testing we found 305 
no plausible eQTL associations in the peripheral blood or brain cortex data (Supplementary 306 
Tables 17-18 and Supplementary Figure 10). In GTEx, however, we found evidence for 307 
overlap from eQTLs in three tissues (Lung, Tibial Artery, and Aorta) at the HPSE2 locus and in 308 
one tissue (Thyroid) at the HEY2 locus (Supplementary Table 19 and Supplementary Figure 309 
15). 310 
 311 
In summary, from three datasets we implicate eQTL signals at only two loci (HPSE2, and 312 
HEY2). This low number (two out of 38) is consistent with previous studies which have observed 313 
that available eQTL catalogues currently lack sufficient tissue specificity and developmental 314 
diversity to provide enough power to provide meaningful biological insight52. No plausibly causal 315 
eQTLs were observed in expression data from brain. 316 
 317 
Gene expression enrichment in specific tissues 318 
To understand if the 38 migraine loci as a group are enriched for expression in certain tissue 319 
groups, we again used the GTEx pilot data61. This time we tested whether genes near to 320 
credibly causal SNPs at the 38 migraine loci were significantly enriched for expression in certain 321 
tissues (Online Methods). We found four tissues that were significantly enriched (after 322 
Bonferroni correction) for expression of the migraine genes (Figure 2). The two most strongly 323 
enriched tissues were part of the cardiovascular system; the aorta and tibial artery. Two other 324 
significant tissues were from the digestive system; esophagus muscularis and esophageal 325 
mucosa. We replicated these enrichment results in an independent dataset using a component 326 
of the DEPICT62 tool that conducts a tissue-specific enrichment analysis on microarray-based 327 
gene expression data  (Supplementary Methods). DEPICT highlighted four tissues (Figure 3 328 
and Supplementary Table 20) with significant enrichment of genes within the migraine loci; 329 
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arteries (P = 1.58 × 10-5), the upper gastrointestinal tract (P = 2.97 × 10-3), myometrium (P = 330 
3.03 × 10-3), and stomach (P = 3.38 × 10-3). 331 
 332 
Taken together, the expression analyses implicate arterial and gastrointestinal (GI) tissues. To 333 
discover if this enrichment signature could be attributed to a more specific type of smooth 334 
muscle, we examined the expression of the nearest genes at migraine loci in a panel of 60 335 
types of human smooth muscle tissue63. Overall, migraine loci genes were not significantly 336 
enriched in a particular class of smooth muscle (Supplementary Figures 11-13). This suggests 337 
that the enrichment of migraine disease variants in genes expressed in tissues with a smooth 338 
muscle component is not specific to blood vessels, the stomach or GI tract, but rather appears 339 
to be generalizable across vascular and visceral smooth muscle types.  340 
 341 
Combined, these results suggest that some of the genes affected by migraine-associated 342 
variants are highly expressed in vascular tissues and their dysfunction could play a role in 343 
migraine. Furthermore, the enrichment results suggest that other tissue types (e.g. smooth 344 
muscle) could also play a role and this may become evident once more migraine loci are 345 
discovered. 346 
 347 
Enrichment in tissue-specific enhancers 348 
To further assess the hypothesis that migraine variants might operate via effects on gene-349 
regulation, we investigated the degree of overlap with histone modifications. We identified 350 
candidate causal variants underlying the 38 migraine loci, and examined their enrichment within 351 
cell-type specific enhancers from 56 primary human tissues and cell types from the Roadmap 352 
Epigenomics64 and ENCODE projects65 (Online Methods and Supplementary Table 21). 353 
Candidate causal variants showed highest enrichment in tissues from the mid-frontal lobe and 354 
duodenum smooth muscle, but these enrichments were not significant after adjusting for 355 
multiple testing (Figure 4).   356 
 357 
Gene set enrichment analyses 358 
To implicate underlying biological pathways involved in migraine, we applied a Gene Ontology 359 
(GO) over-representation analysis of the 38 migraine loci (Online Methods). We found nine 360 
vascular-related biological function categories that are significantly enriched after correction for 361 
multiple testing (Supplementary Table 22). Interestingly, we found little statistical support from 362 
the identified loci for some molecular processes that have been previously linked to migraine, 363 
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e.g. ion homeostasis, glutamate signaling, serotonin signaling, nitric oxide signaling, and 364 
oxidative stress (Supplementary Table 23). However, it is possible that the lack of enrichment 365 
for these functions may be explained by recognizing that current annotations for many genes 366 
and pathways are far from comprehensive, or that larger numbers of migraine loci need to be 367 
identified before we have sensitivity to detect enrichment in these mechanisms.  368 
 369 
For a more comprehensive pathway analysis we used DEPICT, which incorporates gene co-370 
expression information from microarray data to implicate additional, functionally less well-371 
characterized genes in known biological pathways, protein-protein complexes and mouse 372 
phenotypes62 (by forming so-called ‘reconstituted gene sets’). From DEPICT we identified 67 373 
reconstituted gene sets that are significantly enriched (FDR < 5%) for genes found among the 374 
38 migraine associated loci (Supplementary Table 24). Because the reconstituted gene sets 375 
had genes in common, we clustered them into 10 distinct groups of gene sets (Figure 5 and 376 
Online Methods). Several gene sets, including the most significantly enriched reconstituted 377 
gene set (Abnormal Vascular Wound Healing; P = 1.86 × 10-6), were grouped into clusters 378 
related to cell-cell interactions (ITGB1 PPI, Adherens Junction, Integrin Complex). Several of 379 
the other gene set clusters were also related to vascular-biology (Figure 5 and Supplementary 380 
Table 24). 381 
 382 
Discussion 383 
In what is the largest genetic study of migraine to date, we identified 38 distinct genomic loci 384 
harboring 44 independent susceptibility markers for the prevalent forms of migraine. We provide 385 
evidence that migraine-associated genes are involved both in arterial and smooth muscle 386 
function. Two separate analyses, the DEPICT and the GTEx gene-expression enrichment 387 
analyses, point to vascular and smooth muscle tissues being involved in common variant 388 
susceptibility to migraine. The vascular finding is consistent with known co-morbidities and 389 
previously reported shared polygenic risk between migraine, stroke and cardiovascular 390 
diseases66,67. Furthermore, a recent GWA study of Cervical Artery Dissection (CeAD) identified 391 
a genome-wide significant association at exactly the same index SNP (rs9349379) as is 392 
associated to migraine in the PHACTR1 locus, suggesting the possibility of partially shared 393 
genetic components between migraine and CeAD26. These results suggest that vascular 394 
dysfunction and possibly also other smooth muscle dysfunction likely play roles in migraine 395 
pathogenesis.  396 
 397 
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The support for vascular and smooth muscle enrichment of the loci is strong, with multiple lines 398 
of evidence from independent methods and independent datasets. However, it remains likely 399 
that neurogenic mechanisms are also involved in migraine. For example, several lines of 400 
evidence from previous studies have pointed to such mechanisms5,68–71. We found some 401 
support for this when looking at gene expression of individual genes at the 38 loci 402 
(Supplementary Figure 2 and Supplementary Table 25), where many specific genes were 403 
active in brain tissues. While we did not observe statistically significant enrichment in brain 404 
across all loci, it may be that more associated loci are needed to detect this. Alternatively, it 405 
could be due to difficulties in collecting appropriate brain tissue samples with enough specificity, 406 
or other technical challenges. Additionally, there is less clarity of the biological mechanisms for 407 
a brain disease like migraine compared to some other common diseases, e.g. autoimmune or 408 
cardio-metabolic diseases where intermediate risk factors and underlying mechanisms are 409 
better understood.  410 
 411 
Interestingly, some of the analyses highlight gastrointestinal tissues. Although migraine attacks 412 
may include gastrointestinal symptoms (e.g. nausea, vomiting, diarrhea)72 it is likely that the 413 
signals observed here broadly represent smooth muscle signals rather than gastrointestinal 414 
specificity. Smooth muscle is a predominant tissue of the intestine, yet specific smooth muscle 415 
subtypes were not available to test this hypothesis in our primary enrichment analyses. We 416 
showed instead in a range of 60 smooth muscle subtypes, that the migraine loci are expressed 417 
in many types of smooth muscle, including vascular (Supplementary Figure 12 and 13). These 418 
results, while not conclusive, suggest that the enrichment of the migraine loci in smooth muscle 419 
is not specific to the stomach and GI tract.  420 
 421 
Our results implicate cellular pathways and provide an opportunity to determine whether the 422 
genomic data supports previously presented hypotheses of pathways linked to migraine. One 423 
prevailing hypothesis stimulated by findings in familial hemiplegic migraine (FHM) has been that 424 
migraine is a channelopathy5,21. Among the 38 migraine loci only two harbor known ion channels 425 
(KCNK519 and TRPM820), while three additional loci (SLC24A322, ITPK123, and GJA124) can be 426 
linked to ion homeostasis. This further supports the findings of previous studies that in common 427 
forms of migraine, ion channel dysfunction is not the major pathophysiological mechanism15. 428 
However, more generally, genes involved in ion homeostasis could be a component of the 429 
genetic susceptibility. Moreover, we cannot exclude that ion channels could still be important 430 
contributors in migraine with aura, the form most closely resembling FHM, as our ability to 431 
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identify loci in this subgroup is more challenging.  Another suggested hypothesis relates to 432 
oxidative stress and nitric oxide (NO) signaling73–75. Six genes with known links to oxidative 433 
stress and NO, within these 38 loci were identified (REST44, GJA145, YAP146, PRDM1647, 434 
LRP148, and MRVI149). This is in line with previous findings11, however, the DEPICT pathway 435 
analysis observed no association between NO-related reconstituted gene sets and migraine 436 
(FDR > 0.54, Supplementary Table 23).  437 
 438 
Notably, in the migraine subtype analyses, it was possible to identify specific loci for migraine 439 
without aura but not for migraine with aura. However, the heterogeneity analysis 440 
(Supplementary Tables 12-13) demonstrated that most of the identified loci are implicated in 441 
both migraine subtypes. This suggests that no loci were identified in the migraine with aura 442 
analysis mainly due to lack of power from the reduced sample size. Additionally, as shown by 443 
the LD score analysis (Supplementary Figures 5-7), the amount of heritability captured by the 444 
migraine with aura dataset is considerably lower than migraine without aura, such that in order 445 
to reach comparable power, a sample size of two- to three-times larger would be required. This 446 
may reflect a higher degree of heterogeneity in the clinical capture, more complex underlying 447 
biology, or even a larger contribution from low-frequency and rare variation to migraine risk for 448 
this form of the disease. 449 
 450 
In conclusion, the 38 genomic loci identified in this study support the notion that factors in 451 
vascular and smooth muscle tissues contribute to migraine pathophysiology and that the two 452 
major subtypes of migraine, migraine with aura and migraine without aura, have a partially 453 
shared underlying genetic susceptibility profile.454 
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